Compare McKesson Corporation (MCK) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Prudential PLC — how do they compare? McKesson Corporation trades at $824.07 (market cap $97.35B), while Prudential PLC trades at $28.9 (market cap $34.25B). The key difference: McKesson Corporation is far larger — about 2.8× Prudential PLC's market cap, and Prudential PLC pays the higher dividend (1.88%). Which is the better fit depends on your goals.
| MCK | PUK | |
|---|---|---|
Market Cap | $97.35B | $34.25B |
Sector | Health | Financials |
52-Week High | $995.69 | $33.61 |
52-Week Low | $659.01 | $24.74 |
Enterprise Value | $101.98B | $35.69B |
Dividend Yield | 0.39% | 1.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Prudential PLC (PUK) trades at $28.275, showing minimal daily movement with a slight 0.05% decline. The stock presents strong fundamentals with a P/E of 9.21 and robust profitability metrics including 21.15% ROE and 14.52% net income margin. Recent earnings have exceeded expectations, with Q4 2025 EPS beating estimates by 46%. Technical indicators show a bullish overall signal despite mixed moving average signals, while analyst consensus leans positive with 50% buy ratings.
PUK offers attractive value with reasonable valuation multiples and consistent earnings growth, though faces headwinds from regulatory challenges in key markets like Japan and China. The company's strategic expansion in India through the Bharti Life acquisition and strong cash flow generation support long-term growth prospects, but investors should monitor regulatory developments in Asian markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
